BioMarin Pharmaceutical Inc. (0HNC.L) Comparison with companies in other sectors?

BioMarin Pharmaceutical Inc. has a share price of 192.01M. You can analyze BioMarin Pharmaceutical Inc. (0HNC.L) competitors across different market sectors through stock heatmaps.

What are 0HNC.L's NET and operating margins?

BioMarin Pharmaceutical Inc. (0HNC.L) operating margin is around 0.25, and net profit margin is approximately 0.21 as of the latest reports.

In what way does 0HNC.L's earnings per share (EPS) trend reflect its financial momentum?

BioMarin Pharmaceutical Inc. (0HNC.L) EPS is 0.21 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for BioMarin Pharmaceutical Inc. is 270.59, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for BioMarin Pharmaceutical Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for BioMarin Pharmaceutical Inc. like P/E which is 17.03, P/B which is 1.86, and PEG which is 0.68. Compare them with sector averages to evaluate if the stock is priced fairly.

BioMarin Pharmaceutical Inc.

0HNC.L•LSE

Healthcare

Medical - Pharmaceuticals

£58.18

£-0.06(-0.11%)

BioMarin Pharmaceutical Inc. (0HNC.L) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$0.21

P/E Ratio

270.59

ROE

0.11%

Net Margin

0.21%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$11.17B

Shares OutstandingTotal number of shares issued

$192.01M

Book Value/ShareNet worth per share

$31.48

Revenue/ShareAnnual revenue per share

$16.003

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$0.215

Net MarginNet income as percentage of revenue

21.45%

Operating MarginOperating income as percentage of revenue

25.33%

ROEReturn on shareholders' equity

11.48%

ROAReturn on total assets

8.81%

ROCEReturn on capital employed

11.46%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$3.61

Cash/ShareCash and equivalents per share

$7.48

FCF YieldFree cash flow as percentage of market cap

6.16%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 0HNC.LFinancial Ratios Analysis details for 0HNC.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 0HNC.LSector Benchmarking details for 0HNC.L are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for BioMarin Pharmaceutical Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of BioMarin Pharmaceutical Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account BioMarin Pharmaceutical Inc.'s unique business strengths and challenges.

Key Financial Metrics for BioMarin Pharmaceutical Inc.

For BioMarin Pharmaceutical Inc., essential financial indicators include EPS 0.21, PE 270.59, and ROE 0.11. These key ratios reveal insights into BioMarin Pharmaceutical Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare BioMarin Pharmaceutical Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of BioMarin Pharmaceutical Inc.

Metrics like Net Margin 21.45% and ROA 8.81% shed light on how well BioMarin Pharmaceutical Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether BioMarin Pharmaceutical Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of BioMarin Pharmaceutical Inc.

Using ratios such as P/B Ratio 1.86 and PEG Ratio 0.68, investors can assess whether BioMarin Pharmaceutical Inc. is appropriately valued based on its financials and growth potential. These figures, combined with BioMarin Pharmaceutical Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for BioMarin Pharmaceutical Inc.

Financial health indicators, such as Debt/Equity Ratio 0.10 and Cash Flow $3.61, provide a snapshot of BioMarin Pharmaceutical Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like BioMarin Pharmaceutical Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for BioMarin Pharmaceutical Inc.

Investing in BioMarin Pharmaceutical Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at BioMarin Pharmaceutical Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;